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Fig. 1.  Japanese guideline for treatment of ulcerative 
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Simple microspheres Conjugate microspheres 
Fig. 3.  Drug release profiles from simple and conjugate microspheres in 0.05 M 
phosphate buffer, pH 7.4, at 37 oC
Each point represents the mean ? S.D. (n=3).
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Fig. 4.  Particle States of Ch-SP-MS and Ch-SP-MS/EuL100 at 4 h after Incubation at 
37 oC in the JP14 1st Fluid, pH 1.2, JP14 2nd Fluid, pH 6.8, and PBS, pH 7.4



















Results are expressed as the mean ? S.D. (n=160).
Results are expressed as the mean ? S.D. (n=3).
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Before incubation pH 1.2
pH 6.8 pH 7.4
Fig. 7. CLSM micrographs of FITC-Ch-MS after incubation in
different pH media at 37 oC for 4 h
20 µm 20 µm
Fig. 8.  CLSM micrographs of FITC-Ch-MS/EuL and FITC-Ch-
MS/EuS after incubation in different pH media at 37 oC for 4 h 
pH 1.2pH 1.2
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Table 2.  Particle characteristics of PD/EudS 100





PD/EuS 3.73 ? 0.74 1.19 ? 0.26 
Fig. 13.  Effect of substances on T/B in rats with TNBS-induced colitis
The results are expressed as the mean ? S.E. (n=3 – 4).
* P < 0.05 vs. PD(10); # P < 0.05 vs. PD(5) and PD(10)
??????? PD????????????????
?? 1?????????????? 8???????
?????????? PD /EuS??? ???????
???????????? 0.2 - 0.5?g /ml?????
????? 12??????????????????











































































Fig. 18.   Drug release mechanism from Ch-SP-MS (A) and behavior of 
Ch-SP-MS/EuL in the gastrointestinal route (B)
Eudragit layer Ch-SP-MSCh-SP-MS/EuL
Proc? Hoshi Univ. No.51, 2009
? ?? ?
? ? ? ?
1) Karnicki Z.S. WAjtasz-Pajak A., Brzeski M.M., Bykowski P.J., Chtin World, Wirtschaftsverlag NW, Bremerhaven,
1994.
2) Muzzarelli R.A.A., Peter M.G., Chitin Handbook, European Chitin Society, Grottammare, 1997.
3) Sawayanagi Y., Nambu N., Nagai T., Chem. Pharm. Bull., 30, 4216-4218, 1982.
4) Kawashima Y, Handa T., Kasai A., Takanaka H., Lin S.Y., Nando Y., J. Pharm. Sci., 74, 264-268, 1985.
5) Inouye K., Machida Y., Sannan T., Nagai T., Drug Des. Deliv., 4, 55-67, 1989.
6) Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S., J. Pharm. Sci., 86,
1016-1021 (1997).
7) Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A., J. Control. Re
lease, 82, 51-61 (2002).
8) Lamprecht A, Ubrich N, Yamamoto H, Sch?fer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM., J. Pharmacol.
Exp. Ther., 299, 775-781 (2001).
9) Lamprecht A., Sch?fer U., Lehr C.M., Pharm Res., 18, 788-793 (2001).
10) Nakase H., Okazaki K., Tabata Y., Uose S., Ohana M., Uchida K., Matsushima Y., Kawanami C., Oshima C., Ikada
Y., Chiba T., J. Pharmacol. Exp. Ther., 292, 15-21 (2000).
11) Anderson B.D., Conradi R.A., Knuth K.E., Nail S.L., J. Pharm. Sci., 74, 375-381 (1985).
12) McLeod A.D., Friend D.R., Tozer T.N., Int. J. Pharm., 92, 105-114 (1993).
13) Mehvar R., Dann, R.O., Hoganson D.A., J. Control. Release., 68, 53-61 (2000).
14) Yano H., Hirayama F., Kamada M., Arima H., Uekama K., J. Control. Release 79, 103-112 (2002).
15) Onishi H., Oosegi T., Machida Y., McGinity J.W., Drug Dev. Ind. Pharm., 31, 597-605 (2005).
16) Anderson B.D., Conradi R.A., Lambert W.J., J. Pharm. Sci., 73, 604-610 (1984).
17) Yehia S.A., Elshafeey A.H., Sayed I., Shehata A.H., AAPS PharmSciTech. 10, 147-157 (2009).
18) Onishi H., Oosegi T., Machida Y., McGinity J.W., Drug Dev. Ind. Pharm., 33, 848-54 (2007).
19) Oosegi T., Onishi H., Machida Y., Eur. J. Pharm. Biopharm., 68, 260-266 (2008).
20) Akhgari A., Garekani H.A., Sadeghi F., Azimaie M., Int. J. Pharm., 305, 22-30 (2005).
21) Khan M.Z., Stedul H.P., Kurjakovic N., Drug Dev. Ind. Pharm., 26, 549-554 (2000).
22) Oosegi T., Onishi H., Machida Y., Int. J. Pharm., 348, 80-88 (2008).
23) Onishi H., Oosegi T., Machida Y., Int. J. Pharm., 358, 296-302 (2008).
24) ?? ?? ???? (2007).
Development of Novel Delivery System with Conjugate between Chitosan and Anti-inflammatory Drug
Hiraku Onishi
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Inflammatory bowel disease (IBD) is a chronic and refractory disease, but actually there are not necessarily suffi-
cient therapeutic systems. Recently, various drug delivery systems have been developed in an attempt to improve thera-
peutic potentials of drugs for the treatment of IBD. Namely, enhancement of efficacy and reduction of toxic side effects
are targets of their systems. In this research, a conjugate between chitosan and succinyl-prednisolone, Ch-SP, was syn-
thesized, and its microparticulate systems, Ch-SP-MS, were developed. Finally, Eudragit L100-coated Ch-SP-MS, Ch-SP-
MS/EuL, were chosen and evaluated in vitro and in vivo. Ch-SP-MS/EuL protected Ch-SP-MS well at stomach pH, well
delivered PD to cecum and colon, and gradually released PD there, while systemic absorption was suppressed almost
completely. Ch-SP-MS/EuL could achieve enhanced efficacy and reduction of toxic side effect of prednisolone. These con-
jugate microparticles are suggested as a useful delivery system to improve anti-inflammatory therapy by steroidal drugs.
